In experimental animals, survival of TMZ-resistant glioma bearing mice can be improved by combination therapy with a p38 MAPK inhibitor and PD-L1 antibody and this seems to work via a reduction of infiltrating glioma-associated macrophages and PD-L1 expression on resident glioma-associated microglia [193]. The gene discussed is CD274; the disease is central nervous system cancer.